Close this search box.

FDA Hearing Explores Competition & Innovation in Biosimilars

When it comes to how to increase the development and utilization of biosimilars, the Food and Drug Administration is all ears.  On Tuesday, the agency welcomed numerous physicians and experts to testify on competition and innovation in the biosimilars marketplace.  And at least one physician identified a critical component in uptake: physician confidence.

Patents, Progress & Patient Access

Could a recent memorandum from the U.S. Patent and Trademark Office impact treatment options for patients?  Washington, DC’s nonprofit Bipartisan Policy Center says: Yes.